Matthew F. Brown
Pfizer (United States)(US)
Publications by Year
Research Areas
Gastrointestinal Tumor Research and Treatment, Antibiotic Resistance in Bacteria, Cytokine Signaling Pathways and Interactions, Quantum Mechanics and Applications, Synthetic Organic Chemistry Methods
Most-Cited Works
- → Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor(2003)668 cited
- → Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group(2004)442 cited
- → Delineating the role of cooperativity in the design of potent PROTACs for BTK(2018)413 cited
- → Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection(2010)332 cited
- → Chemical and Computational Methods for the Characterization of Covalent Reactive Groups for the Prospective Design of Irreversible Inhibitors(2014)322 cited
- → Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition(2016)191 cited
- → Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S )-2,2-Difluorocyclopropyl)((1 R ,5 S )-3-(2-((1-methyl-1 H -pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)(2018)170 cited
- → Lipid-protein interactions mediate the photochemical function of rhodopsin(1988)164 cited
- → Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases(2018)163 cited
- → Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans(2017)160 cited